In both these studies, pro-inflammatory T helper cells expressing GM-CSF and either CXCR3 or CXCR4 appeared as therapeutic targets for disease-modifying therapies, confirming their relevance in the physiopathology of MS. The gene discussed is CXCR3; the disease is myeloid sarcoma.